Bioventus (BVS) Revenue (2020 - 2026)

Bioventus (BVS) has reported Revenue for 7 consecutive years, with $153.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 3.76% year-over-year to $153.2 million; the trailing twelve-month figure through Jun 2026 stood at $581.8 million (up 3.14% YoY), and the FY2025 full-year result was $568.1 million, down 0.91% from the prior year.
• Revenue rose to $153.2 million in Q2 2026 per BVS's latest filing, from $132.1 million in the prior quarter.
• Across five years, Revenue topped out at $157.9 million in Q4 2025 and bottomed at $117.3 million in Q2 2022.
• Historically, Revenue has averaged $136.2 million across 5 years, with a median of $136.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Revenue surged 43.42% in 2022, then decreased 6.12% in 2023.
• Over 5 years, Revenue stood at $125.8 million in 2022, then grew by 7.62% to $135.4 million in 2023, then climbed by 13.45% to $153.6 million in 2024, then climbed by 2.77% to $157.9 million in 2025, then dropped by 2.97% to $153.2 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $153.2 million, $132.1 million, and $157.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.